| Attribute |
Value |
| 52 Week Change |
-0.59016395 |
| Address1 |
One Commerce Square |
| Address2 |
2,005 Market Street 39th Floor |
| All Time High |
764.6 |
| All Time Low |
3.29 |
| Ask |
5.28 |
| Ask Size |
2 |
| Audit Risk |
7 |
| Average Analyst Rating |
2.3 - Buy |
| Average Daily Volume10 Day |
19,640 |
| Average Daily Volume3 Month |
22,346 |
| Average Volume |
22,346 |
| Average Volume10Days |
19,640 |
| Beta |
1.394 |
| Bid |
2.96 |
| Bid Size |
2 |
| Board Risk |
5 |
| Book Value |
1.385 |
| City |
Philadelphia |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
9 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
3.5 |
| Current Ratio |
1.215 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
3.76 |
| Day Low |
3.37 |
| Display Name |
Passage Bio |
| Dividend Yield |
0.0 |
| Earnings Timestamp End |
1,772,571,600 |
| Earnings Timestamp Start |
1,772,571,600 |
| Ebitda |
-37,579,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
0.343 |
| Enterprise Value |
-12,892,665 |
| Eps Current Year |
-11.34 |
| Eps Forward |
-10.39 |
| Eps Trailing Twelve Months |
-11.33 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
4.48082 |
| Fifty Day Average Change |
-0.9808202 |
| Fifty Day Average Change Percent |
-0.218893 |
| Fifty Two Week Change Percent |
-59.016396 |
| Fifty Two Week High |
20.0 |
| Fifty Two Week High Change |
-16.5 |
| Fifty Two Week High Change Percent |
-0.825 |
| Fifty Two Week Low |
3.29 |
| Fifty Two Week Low Change |
0.21000004 |
| Fifty Two Week Low Change Percent |
0.0638298 |
| Fifty Two Week Range |
3.29 - 20.0 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,582,900,200,000 |
| Float Shares |
3,204,746 |
| Forward Eps |
-10.39 |
| Forward P E |
-0.33686236 |
| Free Cashflow |
-14,814,875 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
24 |
| Fullday Change |
-0.099999905 |
| Fullday Change Percent |
-2.8168988 |
| Fullday Price |
3.5 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,790,812,800 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.07711 |
| Held Percent Institutions |
0.46429002 |
| Implied Shares Outstanding |
3,217,810 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,752,451,200 |
| Last Split Factor |
1:20 |
| Long Business Summary |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania. |
| Long Name |
Passage Bio, Inc. |
| Market |
us_market |
| Market Cap |
11,262,335 |
| Market State |
CLOSED |
| Max Age |
86,400 |
| Message Board Id |
finmb_602462727 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-36,112,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
16,089,050 |
| Number Of Analyst Opinions |
2 |
| Open |
3.61 |
| Operating Cashflow |
-33,500,000 |
| Operating Margins |
0.0 |
| Overall Risk |
7 |
| Phone |
267 866 0311 |
| Previous Close |
3.6 |
| Price Eps Current Year |
-0.30864197 |
| Price Hint |
4 |
| Price To Book |
2.5270758 |
| Profit Margins |
0.0 |
| Quick Ratio |
1.166 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.33333 |
| Region |
US |
| Regular Market Change |
-0.0999999 |
| Regular Market Change Percent |
-2.77778 |
| Regular Market Day High |
3.76 |
| Regular Market Day Low |
3.37 |
| Regular Market Day Range |
3.37 - 3.76 |
| Regular Market Open |
3.61 |
| Regular Market Previous Close |
3.6 |
| Regular Market Price |
3.5 |
| Regular Market Time |
1,792,180,801 |
| Regular Market Volume |
16,804 |
| Return On Assets |
-0.45619 |
| Return On Equity |
-1.69087 |
| Sand P52 Week Change |
0.13723719 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
8 |
| Shares Outstanding |
3,217,810 |
| Shares Percent Shares Out |
0.028199999 |
| Shares Short |
90,840 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
101,638 |
| Short Name |
Passage Bio, Inc. |
| Short Percent Of Float |
0.0352 |
| Short Ratio |
3.35 |
| Source Interval |
15 |
| State |
PA |
| Symbol |
PASG |
| Target High Price |
23.0 |
| Target Low Price |
8.0 |
| Target Mean Price |
15.5 |
| Target Median Price |
15.5 |
| Total Cash |
24,155,000 |
| Total Cash Per Share |
7.507 |
| Total Debt |
0 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-11.33 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
6.88463 |
| Two Hundred Day Average Change |
-3.3846302 |
| Two Hundred Day Average Change Percent |
-0.4916212 |
| Type Disp |
Equity |
| Volume |
16,804 |
| Website |
https://www.passagebio.com |
| Zip |
19,103 |